Qynapse
About Qynapse
Qynapse is a medical technology company that leverages AI-powered neuroimaging software to enhance the precision and reliability of central nervous system (CNS) disease screening and monitoring. Their flagship product, QyScore®, is an FDA-cleared and CE-marked platform that automates the analysis of brain MRI scans. It provides quantitative measures of neuroinflammation and neurodegeneration, including volumetric quantification of segmented brain structures like whole brain, white matter, grey matter by lobe, cerebellum, and white matter abnormalities. This technology aims to support more accurate diagnoses in clinical care and provide objective imaging endpoints for clinical trials.
For physicians, QyScore® offers automated, precise, and data-driven imaging analysis that can integrate seamlessly into existing clinical workflows. It generates rapid, actionable insights and automated patient reports, which can be viewed in a proprietary 3D visualization platform. This can potentially lead to earlier detection, more accurate diagnoses, and better monitoring of disease progression and therapeutic impact for conditions such as Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease. Additionally, Qynapse offers QyPredict®, a research-use-only platform powered by machine learning algorithms, designed to predict disease trajectory and improve patient selection in clinical trials.
Focus Areas
Business Intelligence
| Technology | AI-powered neuroimaging software platform, cloud-based |
What Physicians Need to Know
For physicians, Qynapse's solutions offer empowering, illuminating, and objective data that can significantly enhance clinical decision-making. QyScoreu00ae provides precise, accurate, and reliable readouts, reducing the likelihood of misdiagnosis and supporting timely interventions and tailored treatment plans. The automated patient reports and proprietary 3D visualization platform facilitate easier review and interpretation of complex MRI data. By standardizing image analysis and eliminating inter- and intra-rater variability, Qynapse helps ensure consistent and trustworthy results, ultimately leading to improved patient outcomes and a more personalized approach to long-term care. The cloud-based, easy-to-use platform is designed to scale with patient load, making it a practical tool for both routine clinical practice and research settings.
Qynapse's QyScoreu00ae platform is designed for seamless integration into existing hospital workflows. It is compatible with standard reading environments such as PACS, AV, and AI viewers. The platform supports input from 1.5T and 3T MRI scanners for T1 and T2FLAIR processing and can output results in various formats including DICOM, PDF, and CSV, facilitating data exchange and compatibility within diverse clinical and research infrastructures.
What the Web Says
Qynapse is a medical technology company that specializes in AI-powered neuroimaging analysis for central nervous system (CNS) disorders, such as Alzheimer's, Multiple Sclerosis, and Parkinson's disease. Their flagship product, QyScoreu00ae, is an FDA-cleared and CE-marked software platform that provides automated, high-resolution segmentation of brain structures from MRI scans. The company also offers QyPredictu00ae, a research-use-only platform that utilizes QyScoreu00ae outputs to identify patients likely to experience clinical decline. While there is substantial information about their products and their scientific backing, publicly available independent reviews from platforms like G2, Glassdoor, Capterra, or Reddit are limited.
Overall: PositiveStrengths
- QyScoreu00ae offers precise, automated, and accurate data-driven imaging analysis for personalized clinical support.
- The platform has the potential to improve the accuracy of diagnosis and monitoring for CNS diseases.
- QyScoreu00ae decreases image reading variability and segmentation errors by 89%.
- It has demonstrated better performance compared to certain other state-of-the-art automated methods on the market.
- QyPredictu00ae has shown promise in accurately identifying patients with preclinical Alzheimer's disease and mild cognitive impairment who are likely to experience cognitive decline.
- The platform is cloud-based, easy to use, and integrates seamlessly with existing clinical workflows.
Limitations
- Limited publicly available independent reviews from platforms like G2, Glassdoor, Capterra, and Reddit.
- Specific employer reviews regarding company culture, salaries, or work-life balance are not readily available.
- Lack of detailed user feedback on the day-to-day experience of using Qynapse products outside of company-provided testimonials.
Based on reviews from: Qynapse Official Website, AuntMinnie, PR Newswire, MedicalExpo
Last updated: 2026-07-20
Videos
News, demos, and interviews about Qynapse.
Videos load interactively. If none appear, search YouTube for Qynapse →
Press & Coverage
Frequently Asked Questions
Related Companies
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]
Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]
Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]